Prior Belantamab Exposure Is Associated With Inferior Outcomes With Idecabtagene Vicleucel
July 8, 2025 • CAR-T Content Hub
Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with idecabtagene vicleucel treatment in patients with multiple myeloma. Previous exposure to belantamab was associated with inferior efficacy outcomes with idecabtagene vicleucel. Furthermore, the patients who responded to BCMA-targeted CAR-T therapy did not have a prior response to belantamab treatment. These findings underscore the need to better understand the factors influencing response to different therapies in order to optimize treatment outcomes.
